GU Cancers Symposium 2014 - Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥ 80 years-old: Data from PROCEED - Poster

SAN FRANCISCO, CA USA ( - Presented by Chadi Nabhan, A. Oliver Sartor, Matthew R. Cooperberg, Andrew J. Armstrong, Jeffrey L. Vacirca, Raoul S. Concepcion, William R. Berry, Manish Dhawan, Ronald Tutrone, Andrew Sandler, Candice McCoy, James Boyd Whitmore, Robert Claude Tyler, and Celestia S. Higano at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

gucancer 2014 Nabhan Sip-T thumb


The University of Chicago, Chicago, IL; Tulane Cancer Center, New Orleans, LA; University of California, San Francisco, San Francisco, CA; Duke University, Durham, NC; North Shore Hematology Oncology Associates, PC, East Setauket, NY; Urology Associates, Nashville, TN; Cancer Centers of North Carolina, US Oncology, Raleigh, NC; Highland Clinic, Shreveport, LA; Chesapeake Urologic Research Associates, Baltimore, MD; Dendreon Corporation, Seattle, WA; University of Washington/Seattle Cancer Care Alliance, Seattle, WA